Support IPC Subscribe  Contact Us  Privacy Policy
 twitter facebook LinkedIn YouTube
Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Current Projects

Our projects advance the understanding of psoriasis, improve patient care and support the next generation of psoriasis leaders.

Disease Severity ClassificationDefining disease severity classification
Global Psoriasis Atlas Comprehensive global database on psoriasis
Latin America Working GroupImproving care for patients in Latin America
Scientific Symposia Convening experts to improve the understanding of psoriasis
Biosimilars Working Group Defining how biosimilars can improve access to care
 
now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now


Latest news

Commentary: Dermatologists and SARS - CoV - 2: the impact of the pandemic on daily practice
July 22, 2020
Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage.
Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
July 20, 2020
Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis.
Pathogenesis of Psoriasis
July 14, 2020
Dr. Stingl discusses differences in the pathogenesis of plaque psoriasis and pustular psoriasis. Spoiler alert: it's the neutrophils.
PsoProtectMe now available in multiple languages
July 09, 2020
PsoProtectMe now available in multiple languages
  More News

Advancing Knowledge. Enhancing Care.

 Support Our Work

IPC's mission is to advance the care of people with psoriasis worldwide, through education, research and advocacy.
IPC is not in any way engaged in the practice of medicine or acting as a physician or health care professional or provider. The information IPC publishes is not intended as a substitute for the exercise of professional medical judgement by a health care provider following examination of a patient's condition. The ultimate responsibility for a patient's diagnosis or medical treatment rests with the patient's health care provider.
International Psoriasis Council

1034 S. Brentwood Blvd., Suite 600,
St. Louis, MO USA 63117

Tel (972) 861-0503     Fax (214) 242-3391
email info@psoriasiscouncil.org

© 2020 International Psoriasis Council. All Rights Reserved.

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK